Search clinical trials for: incretins

Total 1811 results

Shanghai Jiao Tong University School of Medicine

Unknown

Study on Exploring the Effect of DPP-4 Inhibitors on β-cell Function by Using the Two-step Hyperglycemic Clamp

Type 2 Diabetes

China
AstraZeneca
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes

Diabetes Mellitus

United States
The First Affiliated Hospital of Xiamen University

Completed

Effect of Short-Term Intensive Insulin Sequential Exenatide Therapy in Newly Diagnosed Type 2 Diabetic Patients

Diabetes Mellitus, Type 2

China
University Health Network, Toronto

Completed

Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon Like Peptide 2

Dyslipidemia

Canada
Merck Sharp & Dohme LLC

Completed

Sitagliptin/Metformin (JANUMET) Re-examination Study (0431A-182)

Type 2 Diabetes Mellitus
ikfe-CRO GmbH
MLM Medical Labs GmbH; Ikfe GmbH

Completed

Effects of Linagliptin on Endothelial- , Renal-, and Retinal Function in Patients With Hypertension and Albuminuria

Albuminuria | Arterial Hypertension

Germany
Boehringer Ingelheim

Completed

Two-way Crossover Study in Healthy Male and Female Subjects to Evaluate the Bioequivalence of Jentadueto®.

Healthy

Russian Federation
AstraZeneca
Eli Lilly and Company

Completed

An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
AstraZeneca

Completed

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea

Diabetes Mellitus, Non-Insulin-Dependent

United States
AstraZeneca

Completed

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin

Diabetes Mellitus, Type 2

United States
AstraZeneca
Eli Lilly and Company

Completed

Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus

United States
AstraZeneca

Completed

Extension Study for 2993-112

Type 2 Diabetes Mellitus

United States, Canada
AstraZeneca
Eli Lilly and Company

Completed

A Study to Examine Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients With Type 2 Diabetes

Type 2 Diabetes

Japan
AstraZeneca

Completed

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Non-Insulin-Dependent

United States
AstraZeneca
Eli Lilly and Company

Completed

Electrophysiological Effects of a Single 10 μg Dose of Exenatide on the 12-Lead Electrocardiogram QT Interval in Healthy Subjects

Healthy Subjects

United Kingdom
AstraZeneca
Eli Lilly and Company

Completed

A Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 In Japanese Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Japan
AstraZeneca
Eli Lilly and Company

Completed

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Exenatide in Adolescent Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
AstraZeneca
Eli Lilly and Company

Completed

Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

United States
AstraZeneca
Eli Lilly and Company

Completed

A Study by Scintigraphy to Evaluate the Effect of Exenatide on Gastric Emptying in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus

United Kingdom
AstraZeneca
Eli Lilly and Company

Completed

Comparison of Exenatide Taken Before Lunch and Dinner With Before Breakfast and Dinner in Patients With Type 2 Diabetes

Type 2 Diabetes

Brazil, Mexico
AstraZeneca
Eli Lilly and Company

Completed

Safety and Efficacy of Exenatide as Monotherapy

Type 2 Diabetes Mellitus

Russian Federation, Romania, United States, India, Puerto Rico
AstraZeneca
Eli Lilly and Company

Completed

Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin

Type 2 Diabetes Mellitus

United States, Spain, Canada
AstraZeneca
Eli Lilly and Company

Completed

Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and Metformin

Type 2 Diabetes Mellitus

Korea, Republic of, China, Taiwan, India
AstraZeneca
Eli Lilly and Company

Completed

Comparing Exenatide and Insulin Glargine in Type 2 Diabetes Patients for Whom Insulin is the Next Appropriate Therapy

Type 2 Diabetes Mellitus

Italy, Poland, Hungary, Mexico, Greece, Australia
AstraZeneca

Completed

Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
AstraZeneca
Eli Lilly and Company

Completed

Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
AstraZeneca
Eli Lilly and Company

Completed

Study of the Safety of Substituting Exenatide for Insulin in Patients Using Insulin and Oral Antidiabetic Agents

Type 2 Diabetes Mellitus

United States
AstraZeneca
Eli Lilly and Company

Completed

Evaluation of the Effect on Glucose Control and Safety of AC2993 in Patients With Type 2 Diabetes Treated With Metformin, Sulfonylurea, or Metformin and Sulfonylurea Combination

Diabetes Mellitus, Type 2

Hungary
AstraZeneca

Completed

Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Non-Insulin-Dependent

United States
Amsterdam UMC, location VUmc

Completed

Effects of Glucagon Like Peptide-1(GLP-1) and Liraglutide on Brain Satiety and Reward Circuits and Feeding Behavior in Diabetes (LIBRA)

Obesity | Type 2 Diabetes

Netherlands
Assistance Publique - Hôpitaux de Paris

Completed

ACute and Chronic Effects of Saxagliptin (ACCES)

Impaired Glucose Tolerance

France
Vastra Gotaland Region
Novo Nordisk A/S

Completed

Addition of Liraglutide to Patients With Type 2 Diabetes Treated With Multiple Daily Insulin Injections

Type 2 Diabetes Mellitus

Sweden
Merck Sharp & Dohme LLC

Completed

An Open-Label, Single- & Multiple-Dose Study to Investigate the Pharmacokinetics of Sitagliptin 100 mg in Healthy Chinese Adult Subjects (0431-108)(COMPLETED)

Diabetes Mellitus Non-insulin-dependent
AstraZeneca
Celerion

Completed

Autoinjector Device Assessment Study (BCB119)

Healthy Subjects

United States
Peter Rossing
Novo Nordisk A/S

Completed

Time Course of the Blood Pressure Lowering Effect of Liraglutide Therapy in Type 2 Diabetes (Liratime)

Type 2 Diabetes

Denmark
Novo Nordisk A/S

Completed

Comparison of Two Liraglutide Formulations in Healthy Subjects

Healthy | Diabetes

Sweden
Takeda

Completed

Pharmacokinetics, Pharmacodynamics, and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
Chinese Academy of Medical Sciences, Fuwai Hospital

Unknown

Efficacy and Mechanism of Exenatide on Improving Heart Function in Type 2 Diabetes With Heart Failure Patients

Heart Failure | Type 2 Diabetes Mellitus
Eli Lilly and Company

Completed

A Study in Participants With Type 2 Diabetes Mellitus (AWARD-1)

Diabetes Mellitus, Type 2

United States, Argentina, Puerto Rico, Mexico
Boehringer Ingelheim
Eli Lilly and Company

Completed

Trial to Assess the Influence of 4 Weeks' Treatment With Linagliptin as Compared to Glimepiride and Placebo on Endothelial Function in Patients With Type 2 Diabetes Using FMD (Flow-Mediated Vasodilation)

Diabetes Mellitus, Type 2

Germany
Janssen Research & Development, LLC

Completed

The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial)

Diabetes Mellitus, Type 2

United States, Canada, France, Poland, Germany, Israel, India, Ukraine, Korea, Republic of, Malaysia, Netherlands, New Zealand, Singapore, Brazil, Austria, Denmark, Belgium
Novo Nordisk A/S

Completed

Bioequivalence of Two Liraglutide Formulations in Healthy Volunteers

Healthy | Diabetes

Sweden
University of Wisconsin, Madison

Completed

Bioenergetic Alterations After Exenatide Administration

Healthy

United States
University Hospital, Basel, Switzerland

Completed

Whole Body 111In-exendin-4 Imaging Study in Insulinoma Patients

Hypoglycemia | Hyperinsulinism | Insulinoma

Switzerland
Alberta Children's Hospital
The Hospital for Sick Children; British Columbia Children's Hospital; Stollery...

Terminated

Safety and Dosing Study of Glucagon-like Peptide 2 (GLP-2) in Infants and Children With Intestinal Failure (GLP-2-01)

Short Bowel Syndrome | Intestinal Failure

Canada
University of Padova

Completed

Rapid Effects Linagliptin on Monocyte Polarization and Endothelial Progenitor Cells in Type 2 Diabetes

Type 2 Diabetes | Chronic Renal Failure

Italy
Novo Nordisk A/S

Completed

Safety of Liraglutide in Subjects With Liver Impairment and in Subjects With Normal Liver Function

Diabetes Mellitus, Type 2 | Diabetes

Poland
Stanford University
Merck Sharp & Dohme LLC

Completed

Study of the Effect of Sitagliptin on Glucose (Sugar) Metabolism in Patients With Heart Failure (S-001)

Heart Failure, Congestive

United States
Rigshospitalet, Denmark

Completed

Hyperglycemia and the Extra-pancreatic Effect of Incretins

Extra-pancreatic Incretin Effect | Glucose Effectiveness

Denmark
Rigshospitalet, Denmark

Completed

Incretins and Metabolism

Type 2 Diabetes

Denmark

3

Subscribe